Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
Pioneering work by a leading University of Nottingham scientist has helped reveal for the first time a vital process in the development of the early mammalian embryo.
Sandia National Laboratories researchers, using off-the-shelf equipment in a chemistry lab, have been working on ways to improve amputees' control over prosthetics with direct help from their own nervous systems.
BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, today announced that TRANSFUSION, the foremost publication in the world for new information regarding transfusion medicine, has published a peer-reviewed journal article reporting positive results of collaborative research on CryoStor, BioLife's serum-free, protein-free cryopreservation freeze media.
A new process for transforming discarded human fat into a soft-tissue substitute for use in reconstructive surgery is laying the groundwork for creating an Ontario-based regenerative medicine initiative focused on developing products for reconstructive and cosmetic surgery.
The biological scaffold that gives structure to a heart valve after its cellular material has been removed can be freeze-dried and stored for later use as a tissue-engineered replacement valve to treat a failing heart, as described in an article in Tissue Engineering, Part C: Methods, a peer-reviewed journal from Mary Ann Liebert, Inc..
Researchers at Northwestern University have developed a new method for creating scaffolds for tissue engineering applications, providing an alternative that is more flexible and less time-intensive than current technology.
Scientists at the University of California, San Diego have developed a new method for making scaffolds for culturing tissue in three-dimensional arrangements that mimic those in the body. This advance, published online in the journal Advanced Materials, allows the production of tissue culture scaffolds containing multiple structurally and chemically distinct layers using common laboratory reagents and materials.
Chronic neuropathic pain following a spinal cord injury is common and very difficult to treat, but a new therapeutic strategy requiring a one-time injection into the spinal column has potential to improve patient outcomes.
BioResearch Open Access, a new bimonthly peer-reviewed open access journal, will launch in March 2012 by Mary Ann Liebert, Inc., publishers.
Researchers at Rice University and Texas Children's Hospital have turned stem cells from amniotic fluid into cells that form blood vessels. Their success offers hope that such stem cells may be used to grow tissue patches to repair infant hearts.
For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.
The rapidly advancing field of tissue injury and repair has an important new forum. Advances in Wound Care will report the latest research findings, innovative wound care strategies, industry product pipeline, and developments in biomaterials and skin and tissue regeneration to optimize patient outcomes.
InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today congratulates Robert S. Langer, Sc.D., InVivo co-founder and member of the Company's Scientific Advisory Board, for his selection as the recipient of the 2011 The Economist annual Innovation Award in Bioscience.
Breast reconstruction surgery will become both safer and more realistic thanks to research led by Queensland University of Technology (QUT) in Brisbane, Australia.
Xeltis, a biomedical technology company developing growing, living and self-healing cardiovascular implants using tissue-engineering technology, has announced conditional approval by the Paul Erlich Institute (PEI) in Germany to commence the first clinical study of its tissue-engineered cardiovascular grafts.
A lab discovery is a step toward implantable replacement cartilage, holding promise for knees, shoulders, ears and noses damaged by osteoarthritis, sports injuries and accidents.
Using magnetic resonance imaging (MRI) and nanoparticle technology, researchers from Yale have devised a way to monitor the growth of laboratory-engineered blood vessels after they have been implanted in patients. This advance represents an important step toward ensuring that blood vessels, and possibly other tissues engineered from a patient's own biological material, are taking hold and working as expected.
A team of scientists from Worcester Polytechnic Institute (WPI) and CellThera, a private company located in WPI's Life Sciences and Bioengineering Center, have regenerated functional muscle tissue in mice, opening the door for a new clinical therapy to treat people who suffer major muscle trauma.
Avita Medical Ltd., the regenerative medicine company, is pleased to announce that it has successfully completed the transfer and acquisition of intellectual property currently licensed through the McComb Foundation of Western Australia.
Bioengineering -- the application of engineering principles to understand and treat medical conditions -- is delivering innovative solutions for diagnosing and repairing damage to the brain caused by a traumatic injury.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.